Beijing: China has taken a significant step in the rapidly evolving brain-computer interface (BCI) industry after approving NEO, a brain-chip system developed by Tsinghua University and Neuracle Technology, for commercial use. The development has sparked global attention, with many observers suggesting China has moved ahead of Elon Musk’s Neuralink in the race to bring brain-chip technology to the market.
The NEO implant is designed primarily to help patients suffering from paralysis and spinal cord injuries regain movement and perform everyday tasks. Chinese regulators approved the device after successful clinical trials, making it the world’s first commercially approved invasive brain-computer interface product.
What Is NEO?
NEO is a coin-sized brain-computer interface that uses sensors placed on the brain’s protective outer membrane, known as the dura mater. The system captures neural signals and converts them into digital commands capable of controlling external devices, including robotic assistive equipment. The technology is intended to help patients recover hand and arm functions lost due to severe spinal injuries.
According to reports, around 36 patients participated in NEO’s clinical trials before it received regulatory clearance. The device is expected to enter broader deployment through China’s healthcare system.
How Does It Compare With Neuralink?
Elon Musk’s Neuralink remains one of the most recognized names in the brain-chip industry. However, Neuralink’s N1 implant is still undergoing clinical testing and has not yet received approval for commercial use. Human trials began in 2024, with a limited number of participants receiving implants.
One key difference is the implantation method. Neuralink’s system uses ultra-thin electrodes inserted directly into the brain’s cortex using a surgical robot. NEO uses a less invasive approach by positioning sensors on the brain’s outer protective layer, which may have helped it move through the approval process more quickly.
Is China Really Ahead?
The answer depends on how “ahead” is defined.
China has clearly achieved a major regulatory milestone by becoming the first country to approve a commercial brain-computer interface product. From a commercialization perspective, NEO currently holds an advantage.
However, the technology race is more complex. Earlier this year, executives from a Chinese state-backed brain-chip company acknowledged that their most advanced invasive systems remain several years behind Neuralink’s technology in some areas, particularly robotic implantation and electrode density.
This suggests that China may be leading in commercial deployment, while Neuralink could still maintain advantages in certain aspects of advanced brain-interface engineering.
Why Brain Chips Matter
Brain-computer interfaces are designed to create direct communication pathways between the human brain and external devices. Researchers believe the technology could transform treatment for:
- Paralysis
- Spinal cord injuries
- ALS and other neurodegenerative diseases
- Stroke recovery
- Vision impairment
- Communication disorders
The long-term goal is to allow patients to control computers, robotic limbs and other devices using only their thoughts.
Challenges and Ethical Concerns
Despite the excitement, experts continue to raise concerns about safety, privacy and cybersecurity. Brain-computer interfaces process highly sensitive neural information, creating questions about data ownership, hacking risks and long-term effects on brain tissue. Researchers emphasize that extensive testing and regulation will remain essential as the technology develops.
A New Front in the US-China Tech Rivalry
The race for brain-chip technology has become the latest battleground in the broader technological competition between the United States and China. Both countries are investing heavily in artificial intelligence, semiconductors, biotechnology and neurotechnology.
With NEO receiving commercial approval before Neuralink, China has secured an important first-mover advantage. Whether it can maintain that lead as more advanced systems emerge remains one of the biggest questions in the future of neurotechnology.
